Romann Alexandra, Beaulieu Monica C, Rhéaume Pascal, Clement Jason, Sidhu Ravindar, Kiaii Mercedeh
British Columbia Provincial Renal Agency, Vancouver, BC - Canada.
Division of Nephrology, University of British Columbia, Vancouver, BC - Canada.
J Vasc Access. 2016 Mar-Apr;17(2):167-74. doi: 10.5301/jva.5000459. Epub 2015 Dec 7.
Improving arteriovenous fistula (AVF) patency is an integral part of the care of hemodialysis patients, often requiring procedures such as percutaneous transluminal angioplasty (PTA). However, these interventions may fail to reduce AVF dysfunction and failure. The purpose of this study was to determine predictive factors for subsequent AVF failure post-PTA.
Data from 155 consecutive AVFs in 155 patients at a single institution who had undergone a first PTA and had at least 1 year of follow-up data were analyzed. Using survival analysis, we assessed primary and secondary patency, and identified predictive factors taking into account competing risks.
Of the 155 patients, 52% required multiple subsequent PTAs; 32% of the AVFs were not in use prior to the first PTA. At first PTA, 83% had outflow vein stenosis (OVS), 26% had multiple stenoses and 43% of stenoses were longer than 2 cm. During follow-up, 1-, 2-, 3-year postintervention primary patency was 41%, 32%, 32% and secondary patency was 80%, 71% and 68%. AVFs with stenoses greater than 2 cm or OVS were at higher risk of requiring multiple PTAs (p = 0.04, 0.006). Factors associated with requiring a second PTA included stenosis greater than 2 cm (hazard ratio (HR) = 1.8, 95% confidence interval (CI) = 1.2-2.9), OVS (HR = 2.5, 95% CI = 1.1-5.4) and primary renal diagnosis of diabetes or renal vascular diseases (HR = 1.8, 95% CI = 1.1-2.9); after adjustments for competing risks, OVS and stenosis length remained associated with requiring subsequent PTAs.
The location and size of the AVF stenosis at first PTA appear to be consistent factors associated with worse postintervention primary patency.
提高动静脉内瘘(AVF)通畅率是血液透析患者护理的重要组成部分,通常需要诸如经皮腔内血管成形术(PTA)等操作。然而,这些干预措施可能无法减少AVF功能障碍和失败。本研究的目的是确定PTA后AVF后续失败的预测因素。
分析了来自单一机构的155例患者的155条连续AVF的数据,这些患者接受了首次PTA并至少有1年的随访数据。使用生存分析,我们评估了初次和二次通畅率,并确定了考虑竞争风险的预测因素。
在155例患者中,52%需要多次后续PTA;32%的AVF在首次PTA之前未使用。在首次PTA时,83%有流出静脉狭窄(OVS),26%有多处狭窄,43%的狭窄长度超过2 cm。在随访期间,干预后1年、2年、3年的初次通畅率分别为41%、32%、32%,二次通畅率分别为80%、71%、68%。狭窄长度大于2 cm或存在OVS的AVF需要多次PTA的风险更高(p = 0.04,0.006)。与需要进行第二次PTA相关的因素包括狭窄长度大于2 cm(风险比(HR)= 1.8,95%置信区间(CI)= 1.2 - 2.9)、OVS(HR = 2.5,95% CI = 1.1 - 5.4)以及糖尿病或肾血管疾病的原发性肾脏诊断(HR = 1.8,95% CI = 1.1 - 2.9);在对竞争风险进行调整后,OVS和狭窄长度仍然与需要后续PTA相关。
首次PTA时AVF狭窄的位置和大小似乎是与干预后初次通畅率较差相关的一致因素。